FDA Approved: OJJAARA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for OJJAARA (momelotinib) from GlaxoSmithKline LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• OJJAARA (MOMELOTINIB)

Snippet

SUPPL AP for OJJAARA (MOMELOTINIB)